Investor Relations

Press Releases

Dec 15, 2017

Repros Therapeutics Inc.® Receives Feedback Following an Oral Explanation with the European Medicines Agency
Read More...

Dec 12, 2017

Repros Therapeutics Inc.® Announces Acquisition by Allergan plc
Read More...

Nov 13, 2017

Repros Therapeutics Inc.® Reports Third Quarter 2017 Financial Results
Read More...

Stock Price

NASDAQ: RPRX
Price:
0.665
Change:
+-0.001
(0%)
Day High:
0.67
Day Low:
0.66
Volume:
69185
4:00 PM ET on Jan 22, 2018
Delayed at least 20 minutes.
Provided by eSignal.

Talking Points

Talking Points

About

We are a development stage biopharmaceutical company focused on the development of oral small molecule drugs for major unmet medical needs in male and female health.

Our current product pipeline (with the respective status of development) consists of the following:

Enclomiphene
Male Reproductive Health

Proellex®
Female Reproductive Health

Read More...

Pipeline

Pipeline
2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3400
281-719-3446 fax